The natural history of chronic allograft nephropathy
- PMID: 14668458
- DOI: 10.1056/NEJMoa020009
The natural history of chronic allograft nephropathy
Abstract
Background: With improved immunosuppression and early allograft survival, chronic allograft nephropathy has become the dominant cause of kidney-transplant failure.
Methods: We evaluated the natural history of chronic allograft nephropathy in a prospective study of 120 recipients with type 1 diabetes, all but 1 of whom had received kidney-pancreas transplants. We obtained 961 kidney-transplant-biopsy specimens taken regularly from the time of transplantation to 10 years thereafter.
Results: Two distinctive phases of injury were evident as chronic allograft nephropathy evolved. An initial phase of early tubulointerstitial damage from ischemic injury (P<0.05), prior severe rejection (P<0.01), and subclinical rejection (P<0.01) predicted mild disease by one year, which was present in 94.2 percent of patients. Early subclinical rejection was common (affecting 45.7 percent of biopsy specimens at three months), and the risk was increased by the occurrence of a prior episode of severe rejection and reduced by tacrolimus and mycophenolate therapy (both P<0.05) and gradually abated after one year. Both subclinical rejection and chronic rejection were associated with increased tubulointerstitial damage (P<0.01). Beyond one year, a later phase of chronic allograft nephropathy was characterized by microvascular and glomerular injury. Chronic rejection (defined as persistent subclinical rejection for two years or longer) was uncommon (5.8 percent). Progressive high-grade arteriolar hyalinosis with luminal narrowing, increasing glomerulosclerosis, and additional tubulointerstitial damage was accompanied by the use of calcineurin inhibitors. Nephrotoxicity, implicated in late ongoing injury, was almost universal at 10 years, even in grafts with excellent early histologic findings. By 10 years, severe chronic allograft nephropathy was present in 58.4 percent of patients, with sclerosis in 37.3 percent of glomeruli. Tubulointerstitial and glomerular damage, once established, was irreversible, resulting in declining renal function and graft failure.
Conclusions: Chronic allograft nephropathy represents cumulative and incremental damage to nephrons from time-dependent immunologic and nonimmunologic causes.
Copyright 2003 Massachusetts Medical Society
Comment in
-
Chronic allograft nephropathy.N Engl J Med. 2003 Dec 11;349(24):2288-90. doi: 10.1056/NEJMp038178. N Engl J Med. 2003. PMID: 14668453 No abstract available.
-
Chronic allograft nephropathy.N Engl J Med. 2004 Mar 18;350(12):1254-6; author reply 1254-6. doi: 10.1056/NEJM200403183501216. N Engl J Med. 2004. PMID: 15028831 No abstract available.
-
Chronic allograft nephropathy.N Engl J Med. 2004 Mar 18;350(12):1254-6; author reply 1254-6. N Engl J Med. 2004. PMID: 15031858 No abstract available.
-
Chronic allograft nephropathy.N Engl J Med. 2004 Mar 18;350(12):1254-6; author reply 1254-6. N Engl J Med. 2004. PMID: 15031859 No abstract available.
-
Chronic rejection and its multifactorial causes.Curr Surg. 2005 May-Jun;62(3):294-9. doi: 10.1016/j.cursur.2004.11.009. Curr Surg. 2005. PMID: 15890211 No abstract available.
Similar articles
-
Kidney allograft outcome in simultaneous pancreas-kidney transplantation.Isr Med Assoc J. 2000 Jul;2(7):517-9. Isr Med Assoc J. 2000. PMID: 10979325
-
Chronic renal allograft dysfunction.J Am Soc Nephrol. 2005 Oct;16(10):3015-26. doi: 10.1681/ASN.2005050463. Epub 2005 Aug 24. J Am Soc Nephrol. 2005. PMID: 16120819 Review.
-
Early acute rejection does not affect chronic allograft nephropathy and death censored graft failure.Transplant Proc. 2004 Dec;36(10):2993-6. doi: 10.1016/j.transproceed.2004.10.070. Transplant Proc. 2004. PMID: 15686679
-
Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.Transplant Proc. 2009 Sep;41(7):2789-93. doi: 10.1016/j.transproceed.2009.07.094. Transplant Proc. 2009. PMID: 19765436
-
Chronic allograft nephropathy.Curr Opin Nephrol Hypertens. 2008 Mar;17(2):149-55. doi: 10.1097/MNH.0b013e3282f4e514. Curr Opin Nephrol Hypertens. 2008. PMID: 18277147 Review.
Cited by
-
Heparanase: A Potential New Factor Involved in the Renal Epithelial Mesenchymal Transition (EMT) Induced by Ischemia/Reperfusion (I/R) Injury.PLoS One. 2016 Jul 28;11(7):e0160074. doi: 10.1371/journal.pone.0160074. eCollection 2016. PLoS One. 2016. PMID: 27467172 Free PMC article.
-
CYP3A5 gene variation influences cyclosporine A metabolite formation and renal cyclosporine disposition.Transplantation. 2013 Mar 27;95(6):821-7. doi: 10.1097/TP.0b013e31827e6ad9. Transplantation. 2013. PMID: 23354298 Free PMC article.
-
Five-year follow-up after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft nephropathy.Int J Clin Exp Med. 2015 Mar 15;8(3):3552-8. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 26064248 Free PMC article.
-
Intra-osseous injection of donor mesenchymal stem cell (MSC) into the bone marrow in living donor kidney transplantation; a pilot study.J Transl Med. 2013 Apr 11;11:96. doi: 10.1186/1479-5876-11-96. J Transl Med. 2013. PMID: 23578110 Free PMC article.
-
Cellular senescence limits regenerative capacity and allograft survival.J Am Soc Nephrol. 2012 Sep;23(9):1467-73. doi: 10.1681/ASN.2011100967. Epub 2012 Jul 12. J Am Soc Nephrol. 2012. PMID: 22797186 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical